Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report
High efficacy of anti-PD-1 therapy has been shown in malignant tumors with mismatch repair deficiency. According to the literature review, mismatch repair deficiency is determined in 20-40 % of all endometrial cancer cases and up to 48 % of its endometrioid subtype. We report the short review of the...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
ABV-press,
2019-07-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | High efficacy of anti-PD-1 therapy has been shown in malignant tumors with mismatch repair deficiency. According to the literature review, mismatch repair deficiency is determined in 20-40 % of all endometrial cancer cases and up to 48 % of its endometrioid subtype. We report the short review of the recent literature and the case of durable partial response on pembrolizumab immunotherapy in a patient with a metastatic endometrioid adenocarcinoma with MMR-deficiency progressed on 2 chemotherapy lines. Partial response was achieved after 6th course, treatment was stopped after 8th course. Patient is on follow-up without any anticancer treatment for 11 months. Partial response lasts for 13 months, with further reduction in tumor size. The treatment was well tolerated without adverse events. |
|---|---|
| Item Description: | 1994-4098 1999-8627 10.17650/1994-4098-2019-15-1-73-77 |